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Abstract 
Background: Sigma (σ) receptors are accepted as a particular receptor class consisting of two subtypes: sigma-1 (σ1) 
and sigma-2 (σ2). The two receptor subtypes have specific drug actions, pharmacological profiles and molecular char-
acteristics. The σ2 receptor is overexpressed in several tumor cell lines, and its ligands are currently under investigation 
for their role in tumor diagnosis and treatment. The σ2 receptor structure has not been disclosed, and researchers rely 
on σ2 receptor radioligand binding assay to understand the receptor’s pharmacological behavior and design new lead 
compounds.
Description: Here we present the sigma-2 Receptor Selective Ligands Database (S2RSLDB) a manually curated data-
base of the σ2 receptor selective ligands containing more than 650 compounds. The database is built with chemical 
structure information, radioligand binding affinity data, computed physicochemical properties, and experimental 
radioligand binding procedures. The S2RSLDB is freely available online without account login and having a powerful 
search engine the user may build complex queries, sort tabulated results, generate color coded 2D and 3D graphs 
and download the data for additional screening.
Conclusion: The collection here reported is extremely useful for the development of new ligands endowed of σ2 
receptor affinity, selectivity, and appropriate physicochemical properties. The database will be updated yearly and in 
the near future, an online submission form will be available to help with keeping the database widely spread in the 
research community and continually updated. The database is available at http://www.researchdsf.unict.it/S2RSLDB.
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Drug design, Central nervous system multiparameter optimization, Lipinski’s rule of five
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Background
Sigma (σ) receptors are accepted as a particular recep-
tor class consisting of two subtypes: sigma-1 (σ1) and 
sigma-2 (σ2). They are distinguished by molecular weight 
(MW), drug actions, pharmacological profiles and molec-
ular characteristics [1, 2]. The σ1 receptor has a MW of 
25.3 kDa and was first cloned from guinea pig liver (Uni-
ProtID Q60492, Gene names SIGMAR1, CHEMBL4153) 
in 1996 [3, 4], and afterwards from human placental 
choriocarcinoma cell (UniProtID Q99720, Gene names 
SIGMAR1, CHEMBL287) [5]. In addition, the σ1 receptor 
was also cloned by other organisms, like mouse (UniPro-
tID O55242, CHEMBL3465), rat (UniProtID Q9R0C9, 
CHEMBL3602), brushtail possum (UniProtID Q5PXE2), 
ermine (UniProtID Q5PXE3), bovine (UniProtID 
Q58DH7), chicken (UniProtID Q5ZL84), and zebrafish 
(UniProtID Q7ZWG9). Recently the crystal structures of 
the human σ1 receptor in complex with two ligands, has 
been reported (PDB ID 5HK1 and 5HK2) [3, 6].
The σ2 receptor has not yet been cloned or crystal-
lized and the knowledge about this receptor has mostly 
been generated through in  vitro receptor radioligand 
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binding studies [7, 8]. As reported the σ2 receptor has 
a MW between 18 and 21 kDa [9, 10]. It has been pos-
tulated that the σ2 receptor binding site may be located 
in the progesterone receptor membrane component 1 
(PGRMC1), even if its MW (25  kDa) is different from 
that of σ2 receptor [10, 11].
The σ1 receptor is involved in aging and various dis-
eases, like schizophrenia, depression, Alzheimer’s dis-
ease and ischemia. The σ1 receptor agonists have showed 
neuroprotective, anti-amnestic and antidepressant effects 
[12–14]. Conversely, σ1 receptor antagonists are consid-
ered antiproliferative, antiangiogenic and to have modu-
latory effects on opioid analgesia [15–17]. Some studies 
suggested that σ1 receptor is involved in modulating the 
synthesis and release of dopamine and also to act as a 
molecular chaperone at the mitochondrion-associated 
endoplasmic reticulum membrane (MAM) where it reg-
ulates calcium signaling between the two organelles [4, 
18–20].
Despite the lack of structural information, the σ2 recep-
tor has gained remarkable attention due to its involve-
ment in several human diseases, including but not 
limited to depression, anxiety and cancer diagnosis and 
treatment [21–23]. The σ2 receptor ligands determine 
tumor cell death through apoptotic and non-apoptotic 
pathways, although their mechanisms of action have 
not been fully elucidated [24, 25]. In addition, the over-
expression of σ2 receptor in several tumor cell lines is 
noteworthy [26–28]. The σ2 receptor is expressed about 
tenfold more in proliferating tumor cells compared with 
quiescent tumor cells, keeping the σ2 receptor ligands 
highly indicate for ligand-targeted cancer therapeutic 
strategies and as imaging agents [23, 29–32]. This pecu-
liarity has been used for the development of σ2 receptor 
selective ligands as Positron Emission Tomography (PET) 
imaging tools. [18F]ISO-1, a promising PET ligand tar-
geting σ2 receptor, has been evaluated in clinical trial for 
the assessment of cellular proliferation in tumors by PET 
and three additional phase I clinical trials on this com-
pound are actually ongoing [33–36]. These differences in 
the pharmacological profiles of the σ receptor subtypes, 
prompt to a continue research of ligands that selectively 
target each of them. However, whilst several ligands 
selectively bind to the σ1 receptor or indistinctly to the 
two receptor subtypes, the development of compound 
endowed with high selectivity for the σ2 receptor has 
been challenging and in some cases occurred through an 
accidental discovery [23].
Due to the lack of structural information about the σ2 
receptor and its growing implication in cancer diagno-
sis and treatment, a thorough and in-depth collection of 
the selective σ2 receptor ligands could result in a helpful 
tool for drug discovery. Herein, an online ligand database 
named sigma-2 Receptor Selective Ligands Database 
(S2RSLDB) based on 2D structural information, com-
puted physicochemical properties, pharmacological 
properties together with the experimental procedure 
protocols, retrieved from the literature, has been built 
and resulted in more than 650 compounds. The data-
base contains all the ligands that selectively bind the σ2 
receptor (i.e. Ki σ1/σ2 > 1). The S2RSLDB is freely avail-
able online without account login and having a powerful 
search engine the user may build complex queries, sort 
tabulated results, generate color coded 2D and 3D graphs 
and download the data for additional offline screening.
The collection here reported is extremely useful for the 
development of ligands endowed of σ2 receptor affinity, 
selectivity, and appropriate physicochemical properties. 
To the best of our knowledge, there is not any online 
database reporting such complete compounds map for 
this receptor. Moreover, in most cases these do not allow 
a comparison between the compound’s features and a 
complete and correct set of compounds is difficult to be 
returned. The database will be updated yearly and in the 
near future, an online submission form will be available 
to help with keeping the database widely spread in the 
research community and continually updated.
Description and utility
Compound information was manually retrieved from the 
literature, including journal articles and patents, which 
were selected using major databases like Pubmed [37], 
SciFinder [38], and Google. The Binding Database [39], 
ChEMBL (v21) [40], PubChem [41], PDBbinding [42], 
ChemSpider [43], as well as other online ligand data-
bases, were also checked for completeness. For each lit-
erature source, a curator manually constructed the 2D 
chemical structures using Marvin Sketch (v14.9.1.0) [44] 
and converted them into SMILES strings using JChem 
for Excel (v14.9.100.809) [44]. For few publications, the 
Optical Structure Recognition Application (OSRA) soft-
ware (v2.0.1) was employed to generate SMILES [45]. A 
SMILES file was generated and then converted them into 
structures using JChem for excel (v14.9.100.809) [44]. A 
second curator visually inspected for common structure 
mistakes. Once a full list of compounds was available, 
compound structures were verified in SciFinder [38], pat-
ent and journal articles by SMILES or 2D structure vis-
ual inspection. Finally, Open Babel (v2016-01) was used 
to create InChI strings that in turn were used to remove 
duplicates from the S2RSLDB [46].
Other information taken from the literature includes 
the radioligand binding affinity values (Ki or IC50 
expressed in nM or otherwise converted in nM), the 
experimental procedure protocols [47], the refer-
ence article compound key and/or preferred name (e.g. 
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CM-361; 9f ), and the compound formulation (free base 
or salt) used for the displacement binding assay. Those 
compounds presenting numerous binding affinity values, 
resulted from different experimental conditions, have 
been associated with multiple experimental data. Indeed, 
for several compounds, significant variations in bind-
ing assay output values have been encountered and for 
others an inversion in the selectivity ratio (Ki σ1/σ2 < 1) 
has been observed.
S2RSLDB is available online at http://www.research-
dsf.unict.it/S2RSLDB. The database is implemented 
in MySQL (v5.1.73) with Apache (v2.4.20) as the web 
server. For chemical calculation and structure drawing 
Open Babel (v2016-01), Pybel (v2.3.1) and JSME Applet 
Fig. 1 Schematic representation of the S2RSLDB configuration
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(v2015-12-06) are incorporated [46, 48, 49]. Other func-
tions are made available with Python scripts and back-
ground program. The data are stored in MySQL (v5.1.73) 
database. The website is built in HTML, JavaScript, 
CSS and PHP. Compound images have been generated 
through Indigo Toolkit (v1.2.1) [50]. The types of data 
stored and the database structure are illustrated in Fig. 1.
The S2RSLDB has a powerful and intuitive web inter-
face. The search page is divided into five sections: 
structure, computed physicochemical properties, phar-
macological properties, reference search, and S2RSLDB-
ID. Structure search may be performed by either drawing 
a molecule using the JSME Molecular Editor or entering 
a SMILES string as query input. Within the structure 
search, similarity, substructure, and exact search can be 
run. Similarity search employs the FP2 fingerprint, sub-
structure search is performed via SMARTS while exact 
search is done through InChI strings correlation [51–53]. 
By default, the website is set to perform similarity search 
with a Tanimoto coefficient cutoff of zero [51]. With this 
setting, all the compounds in the database are returned 
to the query, and the result webpage will give a tabulation 
of the compounds sorted by Tanimoto coefficient. All the 
aforementioned functionalities are done via Pybel [48].
Physicochemical properties search contains selected 
molecular properties which were calculated for all com-
pounds using ChemAxon’s calculator cxcalc (v6.1.3) [44]. 
These descriptors include MW, octanol–water parti-
tion coefficient (LogP), H-bond donors (HBD), H-bond 
acceptors (HBA), which allow the creation of the Lipin-
ski’s rule of five filter [54]. A Lipinski’s rule of five filter 
checkbox has been incorporated for helping the end user 
in automatically set the filter cutoff. Other descriptors 
include LogD [pH 7.4], topological polar surface area 
(TPSA), atom count, and pKaH (calculated for the most 
basic center). A histogram distribution of these com-
puted physicochemical properties for the compounds in 
the database is presented in Fig. 2. For alignment of the 
key druglike attributes, the central nervous system mul-
tiparameter optimization (CNS MPO) score has been 
calculated for each compound and a CNS MPO score 
box has been included in the search page utility inter-
face [55]. This score (0–6 range) is the sum of a set of six 
normalized (0 to 1 range) physicochemical parameters: 
logP, logD, MW, TPSA, HBD, and pKaH and may help the 
user to predict each compound’s likelihood of CNS activ-
ity and overall better druglike properties [55, 56]. Com-
pounds having a CNS MPO  ≥  4 show better druglike 
Fig. 2 Distribution of the physicochemical properties of the compounds in the database
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properties and are predicted to be centrally acting. [55, 
56]. Furthermore, by activating the CNS MPO attrib-
utes input checkbox the six physicochemical properties 
boxes composing the score, will be returned in the nor-
malized fashion according to the CNS MPO algorithms. 
For each computed physicochemical property, cutoff or 
range can be specified by changing the number in the 
search webpage boxes. In Fig.  3a, Lipinski’s rule of five 
filter was applied together with a substructure search 
of 1,2,3,4-tetrahydroisoquinoline and this returned 67 
hit compounds subjected to the rules. Once the search 
function is launched, matching queries are returned on 
a result webpage in tabulated format displaying main 
pharmacological and computed physicochemical proper-
ties together with the CNS MPO score as well as the 2D 
image of the compounds (Fig. 3b). On condition that the 
CNS MPO input checkbox has been activated, the result 
webpage will show the six computed physicochemical 
Fig. 3 Screenshots of the compound search page set with 1,2,3,4-tetrahydroisoquinoline substructure search and Lipinski’s rule of five filter (a), 
tabulated results page (b), and compound summary page (c)
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properties composing the score normalized according to 
the CNS MPO algorithms. Each compound may thus be 
opened as a summary page (Fig. 3c).
Similar filtering options are available for the pharma-
cological properties search. This search function also 
includes which type of standard constant to be displayed 
(IC50, Ki, and % of inhibition) for both receptors and the 
σ1/σ2 ratio (i.e. selectivity). The reference filter search 
function allows the end user to customize results based 
on journal name, article title, author name, volume, 
issue, page and year of publication. Finally, to help the 
user in retrieving a specific compound from the data-
base S2RSLDB-ID and the reference article compound 
key and/or preferred name (as reported in the literature 
source) searches have been embedded.
The user may build complex queries performing 
searches on a number of fields simultaneously. All the 
numerical fields in the tabulated results webpage can be 
sorted, allowing for an enhanced data analysis. Tabu-
lated result page sorting is accomplished with Sorttable 
(v2) [57]. Compounds can be selected for download in 
excel binary file format (xls). All the entries in the page 
are selected by default and a check-all button lets the user 
select/deselect and then download all the compounds 
displayed. Navigating in the download tab, the full data-
base may be downloaded in two different file formats: 
structure-data file (sdf ) and xls.
Of particular importance for the data set analysis is 
the opportunity to perform graphical analysis of the data 
set or subset. The user may build customized 2D and 3D 
Fig. 4 2D (a) and 3D (b) scatter distribution (website screenshots) of compound’s σ2 Ki versus σ1/σ2 ratio and of compound’s σ2 pKi versus MW 
versus logP color coded by CNS MPO score (2D) and Lipinski’s rule of five filter (3D), and two compounds together with their property summaries
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scatter plots of the compounds selected from the tabu-
lated results page, by defining the axes (eleven variables 
available: Sigma-1 Ki, sigma-2 Ki, sigma-1/Sigma-2 Ki 
ratio, LogP, pKaH, LogD, TPSA, MW, HBD, HBA, and 
CNS MPO) that in turn will compose the Cartesian coor-
dinates of the 2D or 3D graph. A webpage will give the 
scatter plot for the defined axes. A simple linear regres-
sion model has also been added to the 2D graph and 
this feature should let the user to recognize pattern in 
the compound properties behaviour. Being x and y the 
two variables to be plotted, the fitted regression line has 
the following equation: y = ax + b, where a is the slope 
and b is the intercept of the estimated line. Therefore we 
estimated the standard error (se) for a and b, indicated 
on the database 2D plot webpage with se(a) and se(b). 
Finally, the Pearson correlation coefficient ρ is given in 
order to appreciate the data fitting [58]. The aforemen-
tioned functionalities are run with background software. 
The plots dots may also be color coded based on Lipin-
ski’s rule of five violations or CNS MPO score range. A 
three or six color code can been applied as a function of 
the Lipinski’s rule of five violations or CNS MPO score 
range, respectively. Moreover, in the 2D and 3D plot 
webpage, an interactive box has been embedded and this 
feature allows the user to remove from the plot group of 
compounds with specific Lipinski’s rule of five violations 
or CNS MPO score range. The graphs are interactive and 
moving the cursor over a point, will show the coordinates 
as a tooltip, whilst by clicking a point of the graph, the 2D 
image of the selected compound and a properties sum-
mary will be returned in a quadrant. The plotting is made 
available by plotly.js (v1.10.2) [59] which is embedded in 
the website. Since the pharmacological properties (exper-
imental radioligand binding assay) are variables with a 
wide numerical distribution, for plotting purposes, we 
have reported them as −log of the Ki or IC50 (i.e. as pKi 
or pIC50). For the same reason, the σ1/σ2 ratio is showed 
in logarithm scale (log σ1/σ2 ratio). This last function may 
be used prospectively at the design stage to accelerate the 
identification of σ2 receptor ligands with increased prob-
ability of selectivity over σ1 receptor. The plots may be 
downloaded as image files for further offline purposes. 
Figure 4 shows the 2D (a) and 3D (b) scatter distribution 
(website screenshots) of compound’s σ2 Ki versus σ1/σ2 
ratio and of compound’s σ2 pKi versus MW versus logP 
color coded by CNS MPO score (2D) and Lipinski’s rule 
of five filter (3D), and two compounds together with their 
property summaries.
Conclusion
The σ2 receptor structure has not yet been disclosed, and 
radioligand binding assay is primarily used to under-
stand the receptor’s pharmacological behavior and design 
new lead compounds. With this in mind, here we pre-
sent a comprehensive, manually curated, database of the 
σ2 receptor selective ligands containing more than 650 
compounds, built with chemical structure information, 
radioligand binding affinity data, computed physico-
chemical properties, and experimental binding protocols. 
The reported data have been manually retrieved from 
the literature thus keeping this database highly reliable. 
Each compound in the database has the reference source. 
The S2RSLDB is freely available online without account 
login and having a powerful search engine the user may 
build complex queries, sort tabulated results, generate 
2D and 3D color coded graphs and download the data for 
additional offline screening. The collection here reported 
is extremely useful for the development of new ligands 
endowed of σ2 receptor affinity, selectivity, and appropri-
ate physicochemical properties.
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